Skip to main content
Moleculin Biotech, Inc. logo

Moleculin Biotech, Inc. — Investor Relations & Filings

Ticker · MBRX ISIN · US60855D2009 LEI · 549300IB1TLJZCHEO353 US Manufacturing
Open in API
Filings indexed 784 across all filing types
Latest filing 2016-05-03 Capital/Financing Update
Country US United States of America
Listing US MBRX

About Moleculin Biotech, Inc.

https://moleculin.com/

Moleculin Biotech, Inc. is a late-stage clinical pharmaceutical company focused on developing a portfolio of therapeutic candidates for highly resistant cancers and viruses. The company's lead drug candidate is Annamycin, a next-generation liposomal anthracycline designed to be non-cardiotoxic and to circumvent multidrug resistance. Annamycin is being advanced in a pivotal Phase 3 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company's development pipeline also includes other drug candidates targeting hard-to-treat tumors.

Recent filings

Filing Released Lang Actions
424B4
Capital/Financing Update Classification · 95% confidence The document is a 424B4 filing, which is a prospectus related to a securities offering. It details an initial public offering (IPO) of common stock by Moleculin Biotech, Inc., including the number of shares offered, pricing, underwriting arrangements, risk factors, and use of proceeds. The document includes detailed information about the offering and the company's business, but it is not a financial report, earnings release, or management discussion. It is clearly a capital raising document related to the issuance of new shares. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief summary, so it is not a Report Publication Announcement or Regulatory Filing. Hence, the classification is CAP with high confidence.
2016-05-03 English
Regulatory Filings 2016
Regulatory Filings
2016-05-03 English
S-1MEF
Regulatory Filings Classification · 95% confidence The document is a Form S-1 Registration Statement filed with the SEC, specifically a Rule 462(b) filing to increase the maximum aggregate offering price of shares underlying warrants. It is a registration statement related to securities offering, not a financial report, earnings release, or management discussion. The document is a regulatory filing related to capital raising but does not fit into categories like Capital/Financing Update (CAP) which typically covers updates or announcements rather than the registration statement itself. Given the nature of the document as a formal SEC filing for securities registration, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory documents that do not fit other categories. The document length and content confirm it is not a brief announcement or a report publication announcement but a full regulatory filing. Confidence is high due to clear identification of the form and purpose.
2016-05-03 English
8-A12B
Regulatory Filings Classification · 95% confidence The document is a Form 8-A filed with the SEC, which is used for the registration of certain classes of securities pursuant to Section 12(b) or 12(g) of the Securities Exchange Act of 1934. It is not a financial report, earnings release, or management discussion. The document primarily serves as a registration statement for securities listing on an exchange (NASDAQ). It does not contain financial statements or detailed financial data. Given the nature of Form 8-A filings, this falls under the category of Regulatory Filings (RNS) as it is a compliance document related to securities registration rather than a report or announcement of financial results or corporate actions.
2016-04-28 English
Regulatory Filings 2016
Regulatory Filings Classification · 95% confidence The document is a letter from Bonwick Capital Partners to the SEC regarding a Registration Statement No. 333-209323 for Moleculin Biotech, Inc. It requests acceleration of the effective date of the registration statement and confirms compliance with distribution rules for the Preliminary Prospectus. This is a correspondence related to a securities registration process, specifically concerning the timing and distribution of a prospectus. It does not contain financial statements, audit information, or detailed report content. It is not a report itself but a regulatory communication related to a capital raising process. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2016-04-28 English
Capital/Financing Update 2016
Capital/Financing Update Classification · 95% confidence The document is a letter from Moleculin Biotech, Inc. to the SEC requesting acceleration of effectiveness for a Registration Statement on Form S-1. It references Rule 461 of the Securities Act of 1933 and discusses the process of the registration statement becoming effective. There is no financial data, report content, or detailed disclosures typical of financial reports. The document is a regulatory communication related to a capital raising registration statement, specifically a request for acceleration of effectiveness. This fits the category of Capital/Financing Update (CAP), as it pertains to the company's fundraising process and registration statement effectiveness. The document length is short and it is not an announcement of a report publication, nor a certification or proxy material. Therefore, the best classification is CAP with high confidence.
2016-04-28 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.